Obtenga las últimas noticias sobre las acciones de Moderna con actualizaciones sobre las tendencias del mercado, las finanzas y el análisis de Benzinga. Manténgase informado sobre el rendimiento de MRNA

Últimas noticias sobre

MODERNA INC

Moderna

Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.

Usa,President,Donald,Trump,On,Smartphone,And,Stock,Image,In

Analyst Color

Government

Regulations

Sector ETFs

Health Care

ETFs

BIIB

MRNA

TECH

El acuerdo de Trump con Pfizer impulsa las acciones del sector sanitario y marca un precedente en precios de medicamentos en EE.UU.Etiquetas:

Acciones del sector sanitario se disparan tras acuerdo Trump-Pfizer

Rovi Laboratorios

ALMRY

GRFS

Jefferies ha reiterado su recomendación de compra sobre Laboratorios Farmacéuticos Rovi (BME:ROVI) tras reunirse con su director financiero (CFO). El interés del banco se apoya en tres palancas operativas y en un marco de objetivos a 2030 que prioriza crecimiento rentable y diversificación.

Acciones de Rovi (ROVI) reciben respaldo de Jefferies con potencial superior al 20 %

Independent,Presidential,Candidate,Robert,F.,Kennedy,Jr.,Announced,'no,Spoiler'

NVAX

El Departamento de Salud de EE. UU. bajo RFK Jr. cancela contratos mRNA y apuesta por vacunas de virus completo y plataformas innovadoras.

HHS cancela 22 proyectos de vacunas mRNA por 500 millones de dólares

Moderna Inc

Legal

Press Releases

Moderna Receives U.S. FDA Approval for Updated COVID-19 Vaccines Targeting LP.8.1 Variant of SARS-CoV-2

IQVIA and Flagship Pioneering Announce Strategic Collaboration to Accelerate the Development of Breakthrough Life Sciences Companies

Events

Moderna Announces Data to be Presented at the 2025 International Congress of Inborn Errors of Metabolism

News

Moderna Announces Updated COVID-19 Vaccine Against LP.8.1 Variant Generates Strong Immune Response in Humans

Moderna Announces First Made-in-Canada mRNA Vaccines Delivered to Canadian Provinces and Territories

Moderna Announces mNEXSPIKE Generates Strong Immune Response Against LP.8.1 Variant in Humans

Moderna Opens State-of-the-Art Manufacturing and R&D Facility in the UK

Moderna Presents Promising Early Data for Its Investigational Cancer Antigen Therapy at the 2025 European Society for Medical Oncology Congress

Earnings

Moderna to Report Third Quarter 2025 Financial Results on Thursday, November 6, 2025

Moderna Highlights Seasonal Flu and H5 Pandemic Flu Candidates at IDWeek 2025

FHTX

SANA

AbbVie

Alnylam Pharmaceuticals, Inc. - Common Stock

Alnylam Pharmaceuticals

Amgen

argenx

Ascendis Pharma A/S - American Depositary Shares

Ascendis Pharma

BridgeBio Pharma

Biogen

BioMarin Pharmaceutical Inc. - Common Stock

BioMarin Pharmaceutical

BioNTech

Exact Sciences Corporation - Common Stock

Exact Sciences

Exelixis

Gilead Sciences

Genmab

Incyte

Insmed

Ionis Pharmaceuticals, Inc. - Common Stock

Ionis Pharmaceuticals

Neurocrine Biosciences, Inc. - Common Stock

Neurocrine Biosciences

Natera

BeOne Medicines Ltd. - American Depositary Shares

BeOne Medicines

Regeneron Pharmaceuticals, Inc. - Common Stock

Regeneron Pharmaceuticals

Roivant Sciences

Revolution Medicines, Inc. - Common Stock

Revolution Medicines

Summit Therapeutics

United Therapeutics Corporation - Common Stock

United Therapeutics

Vertex Pharmaceuticals Incorporated - Common Stock

Vertex Pharmaceuticals

Morgan Stanley

Leerink Partners

Barclays

B of A Securities

JP Morgan

Screenshot 2024-04-30 at 5.36.02 PM

General

Cardio Diagnostics Holdings Inc. - Common stock

CDIO

3 Trends In Healthcare Guided By AI And The Companies Behind The Innovation

Screenshot 2024-03-13 at 5.45.52 PM

Biotech

FDXTF

SHTDY

Nanotechnology&#39;s Promising Role In Fighting Infectious Diseases: Protecting Surfaces With FendX&#39;s Nanotechnology

WIIM

Moderna shares are trading higher after the company presented data at IDWeek 2025 showing its mRNA-1010 and mRNA-1018 vaccines generated rapid immune responses with no safety concerns across adult populations.

Comments

Moderna Noticias bursátiles

Noticias

Últimas noticias sobre

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL